CD44 and ovarian carcinoma: The non-kinase transmembrane receptor CD44 represents a promising therapeutic target for ovarian cancer treatment, as it has been implicated in the development of chemoresistance, maintenance of cancer stem cells, and promotion of metastatic progression through diverse mechanisms (Martincuks et al., 2020).